Clinical trials: Type A Botulinum Toxin
Cerebral Palsy
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
The purpose of the study is to compare the effectiveness of 3 doses of Dysport (5, 10 or 15 Units/Kg/hip) in the management of chronic bilateral hip pain due to cerebral palsy in children/young people.
- Trial name
- NCT00455637
- Testing
- Botulinum toxin type A
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Ipsen
Botulinum Toxin Type A, Rives Repair
Botulinum Toxin to Avoid Component Separation in Midline Large Hernias
Introduction. The goal of our study was to compare results in patients with large midline incisional hernia (LMIH) using only anterior compònent separation (CST) versus preoperative botulinum toxin (BT) and following Rives repair…
- Conditions
- Botulinum Toxin Type A, Rives Repair, Large Midline Hernia, Component Separation
- Trial name
- BTCS01 (NCT04131348)
- Testing
- botulinum toxin type A
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Universitario La Fe
Spasticity, Cerebral Palsy
Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT
Spasticity is a motor disorder that can affect the lower limbs in up to 75% patients with cerebral palsy, having a significantly effect on their mobility and quality of life.
- Trial name
- NCT02400619
- Testing
- shock waves, Botulinum Toxin Type A
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Xavi Vidal Novellas
Cerebral Palsy, Post-operative Pain
The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial
Cerebral palsy is common. It affects approximately 3 per 1000 children. Hip displacement due to muscle tightness (spasticity) occurs in up to half of the more severely affected children, and many of these children require major…
- Trial name
- POPPIES (NCT01437644)
- Testing
- botulinum toxin intramuscular injection
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Strabismus
Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position.
- Trial name
- NCT01584843
- Testing
- GSK1358820
- Where
- 13 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Freezing of Gate, Parkinson Disease
Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.
Freezing of gait is a symptom of Parkinson's disease (PD) that becomes more evident with the evolution of the disease, and which presents an important difference compared to the other signs and symptoms: does not respond…
- Conditions
- Freezing of Gate, Parkinson Disease, Botulinum Toxin
- Trial name
- NCT06094309
- Testing
- Botulinum toxin type A injection
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- Centro Hospitalar de Lisboa Central
Scar
A Dosage-dependent Manner of Botulinum Toxin Type A on the Prevention of Postoperative Scars of Various Anatomic Regions of the Body
Each year, millions of burn, trauma, or surgical patients worldwide suffer from scarring that severely affects their quality of life and social functioning.
- Trial name
- NCT06349733
- Testing
- Botulinum toxin type A
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University
Lower Limb Spasticity Due to Cerebral Palsy
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle…
- Trial name
- NCT01893411
- Testing
- IncobotulinumtoxinA (16 Units per kg body weight), IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight)
- Where
- 53 sites in Austria, Czechia and 12 more
- Volunteers
- 311 people
- Sponsor
- Merz Pharmaceuticals GmbH
Cerebral Palsy
Safety on Switching Between Different Botulinum Toxin-A
Clinical guidelines recommend the use of Botulinum Toxin-A (BoNT-A) for localized/segmental spasticity in children with cerebral palsy.
- Trial name
- NCT03234413
- Testing
- Botulinum toxin type A
- Where
- Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Nigar Dursun
Cerebral Palsy, Spastic, Physical Therapy
Effect of Botulinum Toxin Type A Associated With Physical Therapy on Children With Spastic Cerebral Palsy
Purpose: The aim of this study was investigate the effects of botulinum toxin type A (BoNT-A) associated with physical therapy on the functional capacity of children with spastic cerebral palsy (CP).
- Conditions
- Cerebral Palsy, Spastic, Physical Therapy, Botulinum Toxin
- Trial name
- NCT03704155
- Testing
- Botulinum toxin type A, Physical Therapy
- Volunteers
- 24 people
- Sponsor
- University of Nove de Julho
Spastic Cerebral Palsy
INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)
Prospective, open-label, non-randomized, single-arm, dose titration, phase II study. The study will consist of three injection cycles. In each, an injection visit is followed by an observation period of 12 to 20 weeks.
- Trial name
- INCIPIT (NCT05340439)
- Testing
- IncobotulinumtoxinA 100 UNT [Xeomin]
- Volunteers
- 30 people
- Sponsor
- Universita di Verona
Cerebral Palsy
Sarcopenia and Osteopenia in Individuals With Cerebral Palsy and Influences After Botulinum Neurotoxin Type A Injection
Botulinum neurotoxin type A (BoNT-A) intervention to control the hypertonia of muscles is one of the evidence-based managements for children with spastic cerebral palsy.
- Trial name
- NCT05207124
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Cheng-Kung University Hospital
Idiopathic Clubfoot (Talipes Equinovarus)
A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot
The purpose of this study is to continue the work from the previous review study and determine the effectiveness of Botox in treating patients with idiopathic clubfoot by comparing outcomes of subjects treated with manipulation…
- Trial name
- NCT00152347
- Testing
- Botox
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University of British Columbia
Wilson Disease
The Clinical Study of Botulinum Toxin Type A Injection in the Treatment of Wilson Disease
In order to expand the treatment of Wilson disease and improve the quality of life of patients with Wilson's disease, the clinical effect of botulinum toxin type A injection on Wilson's disease was discussed.
- Trial name
- WD (NCT06762509)
- Testing
- Botulinum toxin type A
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Cerebrovascular Accident
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities
Stroke may result in lower extremity spasticity, which interfere with motor voluntary function and activities of daily living. Botulinum toxin type A (BTX-A) has been shown to improve lower extremity spasticity of stroke…
- Trial name
- NCT02469948
- Testing
- Botulinum toxin type A
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Neuropathies
Botulinum Toxin Type A in Diabetic Peripheral Neuropathy
Background: Diabetes mellitus is commonly complicated by diabetic peripheral neuropathy. Due to common side effects and poor tolerance to medication, poor adherence to medication is common in diabetic peripheral neuropathy.
- Trial name
- NCT05296759
- Testing
- botulinum toxin A, Gabapentin, Duloxetine
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
Efficacy of 200 IU OnabotulinumtoxinA in Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
This study aimed to assess the efficacy and safety of onabotulinumtoxinA (botulinum toxin type A) in patients with idiopathic overactive bladder (OAB) and urinary incontinence who had previously failed to respond to…
- Trial name
- NCT06408051
- Testing
- Injection of onabotulinumtoxinA into the bladder wall
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hisar Intercontinental Hospital
Cerebral Palsy, Drooling
Treatment of Drooling With Type A Botulinum Toxin in Children With Cerebral Palsy
The purpose of this study is to evaluate the effectiveness of botulinum toxin injection to treat drooling in children with cerebral palsy, and to find the most appropriate dosage, duration of effect and side effects.
- Trial name
- NCT00173745
- Testing
- botulinum toxin A injection
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Keratoconus
Botulinum Toxin A for the Treatment of Keratoconus
The purpose of this study is to associate the use of botulinum toxin type A for patients with keratoconus to demonstrate that tension eyelid has an important role in disease progression.
- Trial name
- NCT01691651
- Testing
- Subcutaneous injection of botulinum toxin type A, Botulinum Toxin Type A
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Federal University of São Paulo
Hemifacial Microsomia, Facial Nerve Paralysis
Treatment for "Asymmetric Crying Facies"
This study focuses on children with hemifacial microsomia (HFM), a common congenital craniofacial deformity caused by abnormal development of the first and second branchial arches.
- Trial name
- NCT07802639
- Testing
- Botulinium toxin type A injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiaolei Jin